Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma

Beactica Therapeutics has initiated IND-enabling studies for BEA-17, its wholly owned first-in-class oral degrader targeting the epigenetic regulators LSD1 and CoREST. The milestone advances the Swedish precision-medicine company’s preclinical oncology pipeline toward a potential Investigational New Drug filing, though no clinical data, financial terms, or development timeline were disclosed.